Evercore ISI raises Charles River Labs stock price target on revenue growth
Evercore ISI raised its price target for Charles River Laboratories International (NYSE:CRL) to $300 from $260 and kept an Outperform rating, citing a return to organic revenue growth in the first quarter and a DSA book-to-bill of 1.19x. The firm projects 21% adjusted operating income margins for FY2026 and values shares at 23x 2027 earnings.
How this was made
The 30-second read
Why it matters
The primary tradable element is the analyst’s revised valuation and margin framework, which may influence short-term sentiment and options positioning, but it is secondary to any new company guidance or investor-day disclosures.
Market read
A sell-side PT increase tied to specific operating metrics (organic growth, DSA book-to-bill) and a FY2026 adjusted operating income margin projection.
What to watch
The article points to an upcoming September investor day, so near-term price action may be more about positioning for that event than about the PT itself.
Background
Evercore ISI says Charles River Laboratories has shown organic revenue growth recovery and improving biotech demand, and it expects margin expansion into FY2026.
Ticker impact
Evercore ISI raised its Charles River Laboratories price target to $300 from $260 and kept an Outperform rating, citing organic revenue growth and DSA book-to-bill strength.
Near-term bias modestly positive as traders may react to the PT increase, but magnitude likely limited versus primary company disclosures.
This is an analyst target change, not a new company filing or guidance update. The article’s concrete new elements are the PT revision and the specific operating/margin assumptions cited by Evercore ISI.
Market effects
Supports sentiment for contract research and lab services names by reinforcing demand recovery and margin expansion expectations.
No specific regional catalyst beyond US biotech/pharma services sentiment.
Mentions global pharma restructuring completion and R&D normalization, which can broadly support CRO/lab demand expectations.
Counterpoint
Analyst PT hikes can lag or overreact to already-known earnings momentum; without new company guidance, the incremental trading edge may fade quickly.
Key entities
- companyCharles River Laboratories International
Subject of the analyst price target increase, with cited organic revenue growth, DSA book-to-bill strength, and FY2026 margin expectations.
- analyst_firmEvercore ISI
Raised the stock price target to $300 from $260 and maintained an Outperform rating.
